Update (June 25, 2026): Lokivetmab (Cytopoint) — Safety and Dose-Response RCT Evidence in Canine Atopic Dermatitis

Bottom line.

• Lokivetmab (Cytopoint), a caninized anti-canine IL-31 monoclonal antibody, was evaluated in a blinded, randomized, placebo-controlled safety trial of 245 client-owned dogs with chronic atopic dermatitis (AD), with 162 lokivetmab-treated dogs demonstrating no immediate hypersensitivity reactions, no clinically important differences in clinical pathology, and only 2.5% treatment-induced immunogenicity over 42 days.¹
• In a companion blinded, randomized, placebo-controlled dose determination trial enrolling 211 client-owned dogs with chronic AD at 15 referral clinics, lokivetmab at 0.5 and 2.0 mg/kg (subcutaneous single dose on day 0) reduced pruritus compared with placebo for at least 1 month; level and duration of response increased with increasing dose.²
• Pruritus was reported as an adverse event less frequently in the lokivetmab group than the placebo group (4.9% vs 19.3%); a wide variety of concomitant medications was used with no clinically apparent adverse interactions.¹
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Caninized monoclonal antibody; anti-canine interleukin-31 (IL-31) biological.¹
• Mechanism: Binds to and neutralizes soluble IL-31 in dogs; IL-31 is a critical cytokine involved in pruritus in dogs with AD.¹
• Route/interval: Subcutaneous injection; administered monthly in the safety trial (defer specific dose to current labeling and formulary).¹
• Indication discussed here: Control of pruritus associated with atopic dermatitis in dogs.¹
• Key trial populations: Safety trial: 245 enrolled (162 lokivetmab-treated), client-owned dogs with chronic AD, minimal co-morbidity restrictions, no restriction on concomitant medications. Dose determination trial: 211 dogs at 15 referral clinics.^1,2

Managing a dog with chronic atopic dermatitis?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Safety trial design (Michels et al. 2016 — safety)

The safety trial was a randomized, double-blind, placebo-controlled study conducted at 14 veterinary clinics.¹ Dogs were randomized 2:1 to receive lokivetmab (1.0–3.3 mg/kg) or placebo subcutaneously on days 0 and 28. Clinicians examined dogs and collected blood and urine for clinical pathology and immunogenicity assessment on days 0, 28 and 42. Concomitant medications were unrestricted, and co-morbidities were minimally restricted, making this population particularly representative of real-world clinical practice.

Safety outcomes

There were no immediate hypersensitivity reactions (e.g. wheals, vomiting) in any lokivetmab-treated dog.¹ Discomfort at administration occurred in 5.1% of dogs and was similar in frequency and severity between lokivetmab- and placebo-treated groups. Pruritus was reported as an adverse event during the study less frequently in the lokivetmab-treated group (4.9% and 19.3%, respectively); otherwise, adverse events occurred at a similar frequency between treatment groups.¹ There were no clinically important differences between groups in clinical pathology results. Treatment-induced immunogenicity was found in 2.5% of lokivetmab-treated dogs. A wide variety of concomitant medications were used with no clinically apparent adverse interactions.¹

Dose determination trial (Michels et al. 2016 — dose)

The dose determination trial enrolled 211 client-owned dogs with a history of chronic AD at 15 referral clinics.² Dogs were randomized to treatment with lokivetmab (0.125, 0.5 or 2.0 mg/kg) or placebo administered subcutaneously once on day 0. The mean Day 0 Owner Pruritus VAS scores were 7.3, 6.8, 7.3 and 7.0 cm for the placebo, 0.125, 0.5 and 2.0 mg/kg lokivetmab-treated dogs respectively. Lokivetmab at 0.5 and 2.0 mg/kg reduced pruritus compared to placebo for at least 1 month; level and duration of response increased with increasing dose. Further studies were indicated to better understand variability in individual responses across a broader population.²

Mechanism and biological rationale

Lokivetmab is "caninized" — the antibody sequences are modified to resemble those of the target species — to reduce immunogenicity in dogs.¹ All therapeutic monoclonal antibodies retain some immunogenicity; the 2.5% immunogenicity rate observed is consistent with other veterinary biologic agents. Because monoclonal antibodies are not metabolized via cytochrome P450 enzymes, classic pharmacokinetic drug–drug interactions are not anticipated, although cytokine-mediated effects on CYP450 expression remain theoretically possible with narrow-therapeutic-index co-medications such as ciclosporin.¹

How this fits clinical practice

Lokivetmab's monthly subcutaneous dosing offers a practical advantage for dogs whose owners have difficulty with daily oral administration. The safety profile across a diverse population with minimal co-morbidity restrictions and unrestricted concomitant medications is reassuring for real-world patients. The 2015 ICADA guidelines, published before lokivetmab's commercial approval, identify allergen-specific immunotherapy and the listed oral agents as the cornerstone of chronic management; subsequent evidence positions lokivetmab alongside oclacitinib as a biologic option targeting the pruritogenic cytokine axis directly.³ Monthly re-evaluation is appropriate to assess durability of response. Do not infer specific doses from this summary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Michels GM, Walsh KF, Kryda KA, et al. 2016. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol 27(5):505-e136. https://onlinelibrary.wiley.com/doi/10.1111/vde.12364
2. Michels GM, Ramsey DB, Walsh KF, et al. 2016. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 27(5):478-e129. https://onlinelibrary.wiley.com/doi/10.1111/vde.12376
3. Olivry T, DeBoer DJ, Favrot C, et al.; International Committee on Allergic Diseases of Animals. 2015. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11:210. https://pubmed.ncbi.nlm.nih.gov/26276051/

Changelog

• 2026-06-25: First published.